Egalet President and Chief Executive Officer Bob Radie Appointed to Pennsylvania Bio Board of Directors

WAYNE, Pa., May 12, 2015 /PRNewswire/ --  Egalet Corporation (Nasdaq: EGLT) ("Egalet"), a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative pain treatments, today announced Bob Radie, Egalet's president and chief executive officer (CEO), has been appointed to the Pennsylvania Bio board of directors. Mr. Radie is one of nine new directors.    

"We are pleased to elect Egalet CEO Bob Radie to the PA Bio board of directors," said Pennsylvania Bio president and CEO Christopher Molineaux. "As an industry leader with a track record of success and a longtime Pennsylvania resident, Bob will bring insightful contributions to help Pennsylvania Bio remain a valued partner in the life sciences community."

Mr. Radie has been president, CEO and director of Egalet since March 2012. From November 2010 to October 2011, Mr. Radie served as president and CEO of Topaz Pharmaceuticals Inc., a specialty pharmaceutical company acquired by Sanofi Pasteur in 2011. From March 2009 to November 2010, Mr. Radie served as president and CEO of Transmolecular, Inc., a biotechnology company developing cancer diagnostic and treatment products, after serving as a consultant to Transmolecular from December 2008 through March 2009. From September 2007 to September 2008, Mr. Radie served as the chief business officer of Prestwick Pharmaceuticals, Inc., a specialty pharmaceutical company. Before joining Prestwick, Mr. Radie served in senior management positions with a number of pharmaceutical and biotechnology companies, including Morphotek, Inc., Vicuron Pharmaceuticals, Inc. and Eli Lilly and Company. In addition to the Pennsylvania Bio board of directors, Mr. Radie serves as a director of Paratek Pharmaceuticals, a biopharmaceutical company, and Horse Power for Life, a non-profit organization dedicated to improving the quality of life for individuals diagnosed with cancer.

About Pennsylvania Bio
Pennsylvania Bio is the statewide trade association for the life sciences in Pennsylvania and serves as a catalyst to ensure Pennsylvania is a global leader in the life sciences by developing a business and public policy environment which fosters life science growth and success. More information is available at http://www.pabio.org.

About Egalet
Egalet, a fully integrated specialty pharmaceutical company, is focused on developing, manufacturing and commercializing innovative pain treatments. The Company has two approved products: OXAYDO (oxycodone HCI, USP) tablets for oral use only –CII and SPRIX® (ketorolac tromethamine) Nasal Spray. In addition, using Egalet's proprietary Guardian™ Technology, the Company is developing a pipeline of clinical-stage, opioid-based product candidates that are specifically designed to deter abuse by physical and chemical manipulation. The lead programs, Egalet-001, an abuse-deterrent, extended-release, oral morphine formulation, and Egalet-002, an abuse-deterrent, extended-release, oral oxycodone formulation, are in late-stage clinical development for the management of pain severe enough to require daily, around-the-clock opioid treatment and for which alternative treatments are inadequate. Egalet's Guardian Technology can be applied broadly across different classes of pharmaceutical products and can be used to develop combination products that include multiple active pharmaceutical ingredients with similar or different release profiles. Full additional information on Egalet, please visit www.egalet.com.

Please see full prescribing information for OXAYDO at www.oxaydo.com and full prescribing information for SPRIX at www.sprix.com.

Safe Harbor
Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management's current expectations, and are subject to known and unknown uncertainties and risks. Actual results could differ materially from those discussed due to a number of factors, including, but not limited to: the success of our clinical trials, including the timely recruitment of trial subjects and meeting the timelines therefor; our ability to obtain regulatory approval of our product candidates; ability to have third parties manufacture our products; competitive factors; our ability to find and hire qualified sales professionals; general market conditions; and other risk factors described in Egalet's filings with the United States Securities and Exchange Commission. Egalet assumes no obligation to update or revise any forward-looking-statements contained in this press release whether as a result of new information or future events, except as may be required by law.

Investor and Media Contact:
E. Blair Clark-Schoeb
Senior Vice President, Communications
Email: bcs@egalet.com
Tel: 917-432-9275

Logo - http://photos.prnewswire.com/prnh/20140219/NY67493LOGO

SOURCE Egalet Corporation